Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | Emibetuzumab |
Trade Name | |
Synonyms | LY2875358 |
Drug Descriptions |
Emibetuzumab (LY2875358) is MET-targeted antibody, which inhibits binding of the MET ligand HGF and promotes internalization and downregulation of MET, resulting in decreased HGF-dependent and HGF-independent signaling and potentially leading to decreased growth of MET-expressing tumors (PMID: 27803065, PMID: 25231402, PMID: 31622732). |
DrugClasses | MET Antibody 36 MET Inhibitor 59 |
CAS Registry Number | 1365287-97-3 |
NCIT ID | C95732 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Emibetuzumab | Emibetuzumab | 0 | 2 |
Emibetuzumab + Erlotinib | Emibetuzumab Erlotinib | 0 | 2 |
Emibetuzumab + Ramucirumab | Emibetuzumab Ramucirumab | 0 | 1 |
Emibetuzumab + Trametinib | Emibetuzumab Trametinib | 0 | 1 |